Works matching IS 14752867 AND DT 2019 AND VI 19 AND IP 1


Results: 360
    1
    2
    3
    4
    5
    6
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22

    AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models.

    Published in:
    Cancer Cell International, 2019, v. 19, n. 1, p. 1, doi. 10.1186/s12935-019-1059-8
    By:
    • Shaw, Stephen M.;
    • Middleton, Jenny;
    • Wigglesworth, Kim;
    • Charlemagne, Amber;
    • Schulz, Oliver;
    • Glossop, Melanie S.;
    • Whalen, Giles F.;
    • Old, Robert;
    • Westby, Mike;
    • Pickford, Chris;
    • Tabakman, Rinat;
    • Carmi-Levy, Irit;
    • Vainstein, Abi;
    • Sorani, Ella;
    • Zur, Arik A.;
    • Kristian, Sascha A.
    Publication type:
    Article
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32

    S-15 in combination of Akt inhibitor promotes the expansion of CD45RA<sup>−</sup>CCR7<sup>+</sup> tumor infiltrating lymphocytes with high cytotoxic potential and downregulating PD-1<sup>+</sup>Tim-3<sup>+</sup> cells as well as regulatory T cells.

    Published in:
    Cancer Cell International, 2019, v. 19, n. 1, p. N.PAG, doi. 10.1186/s12935-019-1043-3
    By:
    • Xu, Benling;
    • Yuan, Long;
    • Chen, Guangyu;
    • Li, Tiepeng;
    • Zhou, Jinxue;
    • Zhang, Chengjuan;
    • Qin, Peng;
    • Muthana, Musleh M.;
    • Wang, Shengdian;
    • Du, Xuexiang;
    • Gao, Quanli
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50